MRI in Dementia Diagnosis

Indications for Neuroimaging in Dementia

The American College of Radiology recommends anatomical neuroimaging, preferably MRI, in most situations, particularly when cognitive symptoms began within the past 2 years, regardless of progression rate 1
The American College of Radiology recommends MRI when there is an unexpected or unexplained decline in cognition or functional status in a patient with known dementia 1
The American College of Radiology recommends MRI after recent significant head trauma 1
The American College of Radiology recommends MRI when there are unexplained neurological manifestations, such as new severe headache, seizures, Babinski sign, or gait disturbances 1
The American College of Radiology recommends MRI in patients with a history of cancer, particularly with risk for brain metastases 1
The American College of Radiology recommends MRI in patients with risk factors for intracranial bleeding 1
The American College of Radiology recommends MRI when symptoms are compatible with normal pressure hydrocephalus 1
The American College of Radiology recommends MRI in patients with significant vascular risk factors 1

MRI is preferred over CT for detecting vascular lesions and specific dementia subtypes due to its higher sensitivity 1, 2
MRI is recommended for identifying rare conditions that may cause dementia 1

The American College of Radiology recommends FDG-PET scan as an effective tool for differential diagnosis in patients with cognitive impairment whose underlying pathology remains unclear after standard clinical and structural imaging evaluation 1
The American College of Radiology recommends SPECT rCBF study if FDG-PET is unavailable 1
The American College of Radiology recommends limiting amyloid PET imaging to evaluation by dementia experts 1

Advanced MR sequences, such as MR spectroscopy, functional MRI, and diffusion tensor imaging, are not recommended for routine clinical use but may be valuable in research settings 1, 3
Quantification software for MRI is not recommended for routine clinical use pending larger validation studies 1
Semi-quantitative scales, such as the Medial temporal lobe atrophy (MTA) scale, Fazekas scale for white matter changes, and Global cortical atrophy (GCA) scale, are recommended for interpreting MRI and CT scans 1

The Journal of the American College of Radiology recommends MRI without contrast, FDG-PET/CT, and amyloid PET/CT to evaluate for treatable structural abnormalities and support clinical diagnosis in patients with suspected Alzheimer's disease with typical presentation 3, 4

MRI of the brain without intravenous contrast is the preferred initial study for evaluating short‑term memory loss because it provides superior sensitivity for detecting vascular lesions, microhemorrhages, hippocampal atrophy patterns, and rare treatable conditions 5.
When MRI is unavailable, contraindicated, or not tolerated, a non‑contrast head CT is an acceptable alternative, though it is less sensitive than MRI [5][6].

Include a 3‑D T1 volumetric sequence with coronal reformations to allow quantitative assessment of hippocampal volume 6.
Add FLAIR imaging to evaluate white‑matter lesions 6.
Obtain T2‑weighted or susceptibility‑weighted imaging (SWI) when available to improve detection of hemorrhagic or mineralized lesions 6.
Incorporate diffusion‑weighted imaging (DWI) to identify acute pathology such as infarction 6.

If CT is used, request coronal reformations to better visualize hippocampal atrophy [5][6].

Reserve FDG‑PET/CT or amyloid PET/CT for cases where the diagnosis remains unclear after initial MRI/CT and specialist evaluation [5][7]8.
These PET studies should be ordered by dementia specialists or cognitive‑disorder experts [5][6].
When both FDG‑PET and amyloid PET are performed together, they provide greater diagnostic accuracy 8.
PET imaging helps differentiate dementia subtypes when structural imaging does not provide a definitive answer [7][6].
If PET is unavailable, SPECT perfusion imaging can be used as an alternative, though PET is preferred [5][7].

Advanced MRI techniques such as MR spectroscopy, functional MRI, and diffusion tensor imaging are not recommended for routine clinical evaluation of memory loss [5][7].
Intravenous contrast is generally unnecessary for the initial imaging work‑up of short‑term memory impairment 8.
Apply semi‑quantitative visual rating scales when interpreting images, including the medial temporal lobe atrophy (MTA) scale, the Fazekas scale for white‑matter changes, and the global cortical atrophy (GCA) scale [5][7].